<?xml version="1.0" encoding="UTF-8"?>
<p class="p">37 million people are living with human immunodeficiency virus (HIV) infection (
 <ext-link ext-link-type="uri" xlink:href="http://www.unaids.org/" class="ext-link" xmlns:xlink="http://www.w3.org/1999/xlink">www.unaids.org</ext-link>). The so-called “highly active antiretroviral therapy” (HAART), [
 <xref rid="pone.0204042.ref001" ref-type="bibr" class="xref">1</xref>–
 <xref rid="pone.0204042.ref003" ref-type="bibr" class="xref">3</xref>] combinatorial use of 3 or 4 antiretroviral therapeutics (ARTs) determined reduction of the viral load and extension of the patients’ lives. [
 <xref rid="pone.0204042.ref004" ref-type="bibr" class="xref">4</xref>, 
 <xref rid="pone.0204042.ref005" ref-type="bibr" class="xref">5</xref>] However, for an increasing number of patients these medicines lost their efficacy due to the emergence of resistant HIV variants. Development of alternative drugs exhibiting broad and sustained antiretroviral activity against HIV-1 remains a pursued goal to date. [
 <xref rid="pone.0204042.ref006" ref-type="bibr" class="xref">6</xref>]
</p>
